Blood stream infection (BSI) is annually responsible of hundred thousand estimated deaths worlwide. The time frame for identification and antimicrobial susceptibility testing of the causative agent(s) of BSI directly impact the delay in the administration of appropriate antimicrobial therapy and, consequently, the clinical outcome of patients.
MALDI-TOF mass spectrometry obviously revolutionized routine microbial identification by drastically shortening the delay of the identification (ID). There is however no consensus on a universal and affordable tool for shortening the characterization of putative antibiotic resistance mechanisms. IDAREMS aims to introduce a disruptive tool for clinical diagnosis of blood stream infection (BSI) based on targeted proteomics carried out by tandem mass spectrometry (MS) to achieve concomitant pathogen identification and antibiotic resistance profiling directly from an aliquot of positive blood culture in less than one hour.
IDAREMS project is structured over three main work packages: WP1) the development by partner 1 (France) of a prototype assay for concomitant identification and rapid diagnostics of antimicrobial resistance in Gram-negative bacteria using a limited number of antibiotic-resistant bacterial isolates provided by partner 2 (France), partner 3 (Poland) and partner 4 (Thailand); WP2) the validation of the assay through blind testing of new clinical strains; WP3) technician training and deployment of the validated assay in the respective partner’s clinical platforms.
- Jérôme Lemoine, Jérôme Lemoine, France (Coordinator)
- Frederic Robin, Université Clermont Auvergne, France
- Marek Gniadkowski, National Medicines Institute, Poland
- Visanu Thamlikitkul, Mahidol University, Thailand
- Susan M. Poutanen, University of Toronto, Canada